In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage ...

Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available for ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump's inauguration fund, signaling its ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...

Older adults with type 2 diabetes received fewer noninsulin diabetes medications in their final year of life, but insulin use ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of poly(ADP-ribose) polymerase (PARP) inhibitors, are only effective in 5% to 7% of patients.